Verastem Oncology Signs An Exclusive License Agreement With Sanofi For The Development And Commercialization Of COPIKTRA In Russia And CIS, Turkey, The Middle East And Africa; Co. To Receive $5M Upfront, Up To $42M In Milestones
Benzinga Newsdesk